Therefore, the fractionated dose above the threshold (varies between 12 and 18 Gy in different cancer cells) for inducing Trex1 can result in downstream abrogation of IFN-β production, reducing DC recruitment and activation. The gene discussed is TREX1; the disease is cancer.